At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 15 enrolled
Drug / intervention
Amlodipinedrug
Likely dose
Amlodipine 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Calcium Channel Blockade in Primary Aldosteronism
In Brief
A Phase 2 clinical trial evaluating Amlodipine for Primary Aldosteronism and Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral). Completed, enrolled 15 participants across 1 site.
Detailed Summary
This pilot study explore whether the calcium channel blocker amlodipine can lower aldosterone levels in people with primary aldosteronism.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsUniversity of Michigan
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartSep 2020
Primary CompletionDec 2023
TodayJul 2026
First PostedNov 26, 2019
Enrollment StartSep 1, 2020
Primary CompletionDec 30, 2023
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 6.6 years ago
Interventions
Amlodipinedrug
Amlodipine (10mg daily, as tolerated by blood pressure parameters) for 2 weeks